BHST Share Price Performance
US$4.27
-1.33 (-23.75%)
57.3% undervalued intrinsic discount
US$10.00
Fair Value
Price US$4.27
AnalystLowTarget US$10.00
AnalystHighTarget US$15.00
AnalystConsensusTarget US$13.67
Fair ValueUS$10.00
Share Pricen/a
BioHarvest Sciences Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
BHST Community Narratives
AN
Fair Value US$10 57.3% undervalued intrinsic discount
CDMO Pipeline And Capacity Expansion Will Face Setbacks Yet Ultimately Support Future Earnings
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$15 71.5% undervalued intrinsic discount
CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$13.67 68.8% undervalued intrinsic discount
Plant Based CDMO Expansion And Health Pros Network Will Drive Long Term Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
CDMO Pipeline And Capacity Expansion Will Face Setbacks Yet Ultimately Support Future Earnings
Catalysts About BioHarvest Sciences BioHarvest Sciences develops and commercializes plant derived compounds using its patented Botanical Synthesis platform, serving pharmaceuticals, nutraceuticals, cosmetics and nutrition. What are the underlying business or industry changes driving this perspective?Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10
57.3% undervalued intrinsic discount
Fair Value
Profit Margin
17.16%
Future PE
19.59x
Price in 2029
US$12.32
CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power
Catalysts About BioHarvest Sciences BioHarvest Sciences uses its patented Botanical Synthesis platform to produce consistent, highly potent plant based compounds for branded nutraceutical products and contract development and manufacturing services. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
71.5% undervalued intrinsic discount
Fair Value
Profit Margin
15.67%
Future PE
29.1x
Price in 2029
US$18.57
Plant Based CDMO Expansion And Health Pros Network Will Drive Long Term Upside
Catalysts About BioHarvest Sciences BioHarvest Sciences develops and commercializes high value plant derived compounds using its proprietary Botanical Synthesis platform, serving nutraceutical, pharmaceutical, cosmetic and nutrition end markets. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$13.67
68.8% undervalued intrinsic discount
Fair Value
Profit Margin
14.28%
Future PE
34.6x
Price in 2028
US$16.88
Trending Discussion
Recently Updated Narratives
AN
CDMO Pipeline And Capacity Expansion Will Face Setbacks Yet Ultimately Support Future Earnings
Fair Value: US$10 57.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CDMO Pipeline And Hydration Expansion Will Transform Long Term Earnings Power
Fair Value: US$15 71.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Plant Based CDMO Expansion And Health Pros Network Will Drive Long Term Upside
Fair Value: US$13.67 68.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioHarvest Sciences Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.49
- 59.34%
- -32.27%
- 10.1%
About BHST
- Founded
- n/a
- Employees
- 89
- CEO
- WebsiteView website
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional foods, as well as manufacturing, marketing, and sale of science-based health and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company is based in Vancouver, Canada.
Recent BHST News & Updates
